ArticleMicrobiology spectrum2023
The Existing Drug Nifuroxazide as an Antischistosomal Agent:
Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Mapping therapeutic alternatives: a systematic review of preclinical drug repurposing for schistosomiasis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Nifuroxazide and 4-Hydroxybenzhydrazone Derivatives as New Antiparasitic (Pharmaceutics · 2025Article
- Anthelmintic Potential of Conjugated Long-Chain Fatty Acids Isolated from the Bioluminescent MushroomJournal of natural products · 2025Article
- Article
- Exploration of innovative drug repurposing strategies for combating human protozoan diseases: Advances, challenges, and opportunities.Journal of pharmaceutical analysis · 2025Review
- Atomic force microscopy reveals morphological and mechanical properties of schistosoma mansoni tegument.Scientific reports · 2024Article
- Nifuroxazide Prevents Chikungunya Virus Infection BothViruses · 2024Article
- Antihistamines HACS omega · 2024Article
- Article
- Pharmacophore Virtual Screening Identifies Riboflavin as an Inhibitor of the Schistosome Cathepsin B1 Protease with Antiparasitic Activity.ACS omega · 2024Article
- Considering ivermectin for treatment of schistosomiasis.Parasitology research · 2024Article
- Small Schiff Base Molecules-A Possible Strategy to Combat Biofilm-Related Infections.Antibiotics (Basel, Switzerland) · 2024Review
- The 3D pharmacophore modeling to explore new antischistosomal agents among US FDA approved drugs.Future medicinal chemistry · 2024Article
- Evaluating the Antischistosomal Activity of Dehydrodieugenol B and Its Methyl Ether Isolated fromACS omega · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schistosomiasis is a parasitic disease that afflicts approximately 250 million people worldwide. There is an urgent demand for new antiparasitic agents because praziquantel, the only drug available for the treatment of schistosomiasis, is not universally effective and may derail current progress toward the WHO goal of eliminating this disease as a public health problem by 2030. Nifuroxazide (NFZ), an oral nitrofuran antibiotic, has recently been explored to be repurposed for parasitic diseases. Here,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.